United States · Wires & real time · PR Newswire

SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

Published by PR Newswire · United States 1 h ago

Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Associated Press (Business)

8 innovative gifts meant to change up how we drive, cook, sleep and more

Dow Jones Newswires

Rethinking AI in Enterprise Intelligence

MT Newswires

SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

Share

Also worth reading

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot